
    
      The expected time from the first subject's enrollment until the last subject's enrollment is
      approximately 8 months. The screening period is 28 days and each cycle of treatment is 21
      days.

      The number of treatment cycles is not fixed in this study. Subjects who continue to derive
      clinical benefit from the study drug in the absence of withdrawal of consent, progressive
      disease (PD), or unacceptable toxicity may continue the study drug.
    
  